MNX1 and neoplasm: Aberrant expression of MNX1-AS1 has been shown in various tumors, including but not limited to gastric cancer, lung, osteosarcoma, HCC, and ovarian, with its upregulation associated with clinicopathological parameters such as lymphatic metastasis, tumor size, stage, and poor survival [68].